APICMO, a leading producer of pharmaceutical intermediates, announced today that it is has developed — Favipiravir and its intermediates for COVID-19 drugs in bulk supply batches. With this advance, the company is facilitating treatment of COVID-19 on a large scale. The pandemic has caused worldwide demand for the drug to surge, making bulk supply production a necessity for the healthcare industry.
“We are very excited to be able to make this announcement,” said a spokesperson for APICMO. “It’s the result of a great deal of hard work by our research and manufacturing teams. Our hope is that we can make a meaningful contribution to the treatment of this most serious pandemic on a worldwide basis.” As of now, there are over 9 million cases of COVID 19 globally. The death toll from the illness has reached 472,000.
Favipiravir, often sold under the brand name Avigan or Abigan, is an antiviral used to treat influenza and other viral infections. It is also now being deployed to fight COVID-19. The drug is known by its Chemical Abstracts Service (CAS) Registry Number (RN) of 259793-96-9.
APICMO is a pharmaceutical company specializing in key intermediates for new research and development of oncology drugs. The company provides system development, synthetic customization, mass production and other services for drug research and development institutions and pharmaceutical companies. The company is known for the development of chemicals, quality control, cGMP manufacturing, project management, and marketing. APICMO has a strong R&D team and experienced scientists along with a large-scale production plant and business development management team.
For more information, visit https://apicmo.com
Name: Dr. Zeng
Email: Send Email
Organization: apicmo holdings ltd.
Address: Building D, 2 floor, No. 128, Xiangyin Road, Yangpu District, 200433, Shanghai, China
Release ID: 88965219